[HTML][HTML] A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
J Wang, C Deng, M Liu, Y Liu, L Li, Z Huang… - Nature …, 2022 - nature.com
The effectiveness of a 3rd dose of SARS-CoV-2 vaccines waned quickly in the Omicron-
predominant period. In response to fast-waning immunity and the threat of Omicron variant …
predominant period. In response to fast-waning immunity and the threat of Omicron variant …
[HTML][HTML] Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 …
J Serwanga, V Ankunda, J Sembera, L Kato… - Frontiers in …, 2023 - frontiersin.org
Introduction Understanding how spike (S)-, nucleoprotein (N)-, and RBD-directed antibody
responses evolved in mild and asymptomatic COVID-19 in Africa and their interactions with …
responses evolved in mild and asymptomatic COVID-19 in Africa and their interactions with …
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two-or three-dose inactivated COVID-19 vaccine
X Yong, J Liu, Y Zeng, J Nie, X Cui… - Human Vaccines & …, 2023 - Taylor & Francis
ABSTRACT LYB001 is an innovative recombinant SARS-CoV-2 vaccine that displays a
repetitive array of the spike glycoprotein's receptor-binding domain (RBD) on a virus-like …
repetitive array of the spike glycoprotein's receptor-binding domain (RBD) on a virus-like …
[HTML][HTML] mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is highly transmissible and evades pre-established immunity. Messenger RNA …
variant is highly transmissible and evades pre-established immunity. Messenger RNA …
[HTML][HTML] Decreased breadth of the antibody response to the spike protein of SARS-CoV-2 after repeated vaccination
L Horndler, P Delgado, S Romero-Pinedo… - Frontiers in …, 2023 - frontiersin.org
Introduction The rapid development of vaccines to prevent COVID-19 has raised the need to
compare the capacity of different vaccines in terms of developing a protective humoral …
compare the capacity of different vaccines in terms of developing a protective humoral …
Potency assessment of IFNγ-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects
R Gil-Bescós, A Ostiz, S Zalba, I Tamayo… - Life Science …, 2023 - life-science-alliance.org
The development of new therapies for COVID-19 high-risk patients remains necessary to
prevent additional deaths. Here, we studied the phenotypical and functional characteristics …
prevent additional deaths. Here, we studied the phenotypical and functional characteristics …
A SARS-CoV-2 peptide vaccine which elicits T-cell responses in mice but does not protect against infection or disease
VK Baxter, EJ Anderson, SA Taft-Benz, K Olsen… - bioRxiv, 2022 - biorxiv.org
There is significant interest in T-cell mediated immunity against SARS-CoV-2. Both
vaccination and infection have been observed to elicit durable T-cell responses against the …
vaccination and infection have been observed to elicit durable T-cell responses against the …
[PDF][PDF] Jingxin Li, Jiangsu Provincial Center for Disease Control and Prevention, China
G Singh, MZ Tay, J Serwanga, J Serwanga, V Ankunda… - 2023 - scienceopen.com
Methods: Here, we used a validated indirect in-house ELISA to characterise development
and persistence of S-and N-directed IgG, IgM, and IgA antibody responses for 2430 SARS …
and persistence of S-and N-directed IgG, IgM, and IgA antibody responses for 2430 SARS …